[Long-term follow-up of patients with sarcoidosis of respiratory organs].
Long-term (3-25 years) responses to treatment are available for 1820 patients with respiratory sarcoidosis. 65.7% of them were females and 34.3% males primarily at the age of 21-50 (92.7%). Sarcoidosis of the intrathoracic lymph nodes (ITLN), sarcoidosis of the lungs and ITLN, diffuse forms of pulmonary sarcoidosis, generalized sarcoidosis were diagnosed in 64, 28.2, 4.6, 2.6% of patients, respectively. All the patients received combined pathogenetic treatment (hormones, antioxidants, antihypoxants, immunomodulators, angio- and hepatoprotectors) which proved highly long-acting in stage I-II (a complete response rate 84.3% and 82.7%, respectively, residual changes remained in 1/5 of the patients). Long-term recurrences occurred in 3.5% of patients who had marked residual changes in the lungs. The disease took a chronic course in 8.7%, progression was recorded in 9.3, lethal outcome in 0.7% of the cases.
Kostina
Z I
ZI
Brazhenko
N A
NA
Nasorina
R N
RN
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D008171:Lung Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000628:therapy*; D008206:Lymphatic Diseases / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011859:Radiography; D012507:Sarcoidosis / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000628:therapy*; D013997:Time Factors
D000276:Adjuvants, Immunologic; D000975:Antioxidants; D002317:Cardiovascular Agents; D006728:Hormones